Forward-Looking Statements
|
|
|
- Bernard Owen
- 6 years ago
- Views:
Transcription
1 Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
2 Partnering at Bayer February 4, 2015 Kemal Malik, Member of the Board of Management, Bayer AG
3 The New Bayer A Pure Life Science Player Sales Split and Market Positions 2013 By Subgroup Total 40.2bn sales* HealthCare 18.9bn sales Pharmaceuticals 11.2bn, leading positions in core indications Consumer Health 7.7bn, OTC #2, blood glucose meters #3, Animal Health #5, contrast media #1 MaterialScience 11.2bn sales CropScience 8.8bn sales Chemical and biological Crop Protection #2, Seeds & Traits #7, Environmental Science #2 Page 3 Kemal Malik, high-tech partnering conference, February 2015 * Including reconciliation
4 Life Bayer: Influencing a biological System along the Chain-of-Life Page 4 Kemal Malik, high-tech partnering conference, February 2015
5 Facts on Bayer HealthCare 2014 R&D budget EUR 2.28 billion Employees working in R&D* 8122 Patents in Cooperation projects in Page 5 Kemal Malik, high-tech partnering conference, February 2015 * Headcount, as of September 2014
6 One of the Fastest-Growing Global Pharma Companies Pharma Sales Plans for continued growth billion; Δ% Fx & portfolio adj. +4% +1% % % 8.8 Maximize the value of launch products Drive commercial excellence in marketing and sales Advance early and mid-stage pipeline Achieve Phase III readiness for 5 projects in 2015 Explore opportunities for partnerships, open innovation and bolt-on acquisitions Q Page 6 Kemal Malik, high-tech partnering conference, February 2015
7 Pharma Launch Products Drive Growth Combined Peak Sales Potential of 7.5bn Collective Sales billion Q1-Q Individual Sales million ~ ,163 Total 2.1bn e Page 7 Kemal Malik, high-tech partnering conference, February 2015
8 Facts on Bayer CropScience 2014 R&D budget EUR 950 million Employees working in R&D* 5142 Patents in 2013** 263 Cooperation projects in Page 8 Kemal Malik, high-tech partnering conference, February 2015 * Headcount, as of September 2014 ** Plus 188 plant variety protection applications
9 One of the fastest growing Crop Science companies CropScience Sales Plans for continued growth billion; Δ% Fx & portfolio adj. Drive new product growth, invest in life-cycle management % % % % 7.3 Drive commercial excellence in marketing and sales Strengthen portfolio through focused and integrated crop solutions Extend seeds portfolio by building business in soybeans and wheat Q Page 9 Kemal Malik, high-tech partnering conference, February 2015
10 New Products Drive Growth at Crop Protection Sales of New Crop Protection Products by Segment (2013) billion; new products launched since 2006; Δ% y-o-y, fx adj. ~ Insecticides 224 Fungicides +33% 1.5 ~1.8 Total 1.5bn Herbicides 325 Seed Growth e 2016e New products generated 82% of absolute sales growth at Crop Protection Page 10 Kemal Malik, high-tech partnering conference, February 2015
11 High Confidence in R&D of Life Science businesses R&D Budget 2014 R&D Employees 2014 Achievements billion 25 successful Phase III clinical trials at Pharma since Consumer Health 61% Health Care Launched 30 new active ingredients between 2000 and 2013 in CropScience Initiated R&D projects that leverage synergies between human, animal and plant health 1.9 Pharma 0.9 Crop Science 39% Crop Science Strengthened brands through multiple line or product introductions in Consumer Care Total 3.2bn* More than people working in R&D Expect R&D-to-sales ratio to increase Page 11 Kemal Malik, high-tech partnering conference, February 2015 * Plus 0.3bn for Bayer MaterialScience and Reconciliation
12 Bayer focusses on Innovation in therapeutic areas with high unmet medical need Cardiology Hematology Oncology Gynecological Therapy Pulmonary Hypertension / Heart Failure Thrombosis / Acute Coronary Syndrome Cardiorenal Syndrome (CRS) Hemophilia / Rare Bleeding Disorders / Acute Bleeding Hemoglobinopathies Hematopoiesis Cell Cycle/Survival Signaling Immunotherapy/Antibody- Drug Conjugates Tumor Metabolism/ Hypoxia Chromatin Modulation/ OncoGenomics Endometriosis Uterine Fibroids Common Mechanism Research & Other Areas Leveraging the full potential of development compounds Ophthalmology Inflammation LCM Fertility Control / Menopause-Management Magnetic Resonance and Computed Tomography Contrast Media Research Page 12 Kemal Malik, high-tech partnering conference, February 2015
13 Leveraging our exceptional R&D Position to deliver next Generation Products Accelerated discovery of target genes Trait Research Improved selection and classification of lines Breeding Improved quality of candidate selection and lead discovery Chemical Crop Protection Accelerated discovery of leads Biological Crop Protection Page 13 Kemal Malik, high-tech partnering conference, February 2015
14 Tailored partnering models to promote novel treatment options and generate added value Grants4platform Innovative web-based Open Innovation platform to get access to innovative drug targets New company formation Build to buy innovative model for company formation Strategic partnerships with leading institutions Novel type of risk and reward sharing strategic alliance to develop new cancer treatments together with the Broad Institute CoLaborator New Incubator space at Mission Bay and in Berlin to promote collaborations with innovative start-ups Venture Investments Venture Capital Investments to foster early innovation in Life Sciences Page 14 Kemal Malik, high-tech partnering conference, February 2015
15 Bayer is collaborating with leading academic Institutions & Companies worldwide Page 15 Kemal Malik, high-tech partnering conference, February 2015
16 The Bayer open innovation platforms give us access to ideas from the scientific community Bayer HealthCare defines challenge Grants4Targets Start 2009 (12 rounds) 1198 proposals 164 accepted via Internet Grants4Leads Start 2013 (2 rounds) 20 proposals 3 grants provided comes up with ideas and solutions Scientific Community Grants4Apps Start 2013 (3 rounds) 218 proposals 25 accepted Page 16 Kemal Malik, high-tech partnering conference, February 2015
17 CoLaborator facilities in San Francisco and in Berlin benefit both startups and Bayer Assigned lab and office space on Bayer HealthCare s campus at San Francisco (Mission Bay) and in Berlin for start-up companies A new home for startups in life sciences with ideas related to Bayer HealthCare s R&D strategy Proximity to Bayer HealthCare research and the vicinity to surrounding science and startup community create eco-systems for innovative ideas Page 17 Kemal Malik, high-tech partnering conference, February 2015
18 The CoLaborator: Early Results are Demonstrating success on the Concept San Francisco (2,5 years) Berlin (8 month) Element Science, Inc. Partnership is open : SF companies have received follow on collaborations and VC financing from outside parties. Collaborations have launched between Bayer and the tenant companies at both locations: SF (3), Berlin (2) Partnerships developed due to close interaction of scientists from both sides Projects could impact research pipeline, if successful Page 18 Kemal Malik, high-tech partnering conference, February 2015 Contact: USIC@Bayer.com
19 VC Investments: Access to break-through Innovation, Start-ups and Partnering Options Versant Ventures Strategic Investment of up to 25 Mio. USD Major Healthcare fund investing in the USA, Canada and Europe Access to a network of academic centers, entrepreneurs and start-ups Investment in early innovation and firstin-class assets High-Tech Gründerfonds II Investment Volume of 2,5 Mio. EUR Dominant German investor in the seed phase expanding to Biotech Promoting start-up community Attract creative companies to Bayer s CoLaborator in Berlin Page 19 Kemal Malik, high-tech partnering conference, February 2015
20 A strategic alliance supports drug development in ophthalmology Versant Ventures Bayer HealthCare Initiate drug development project through Build-to-Buy model Established network with academic innovators to fuel pipeline Leverage existing Drug Discovery and Development expertise through Inception vehicle Maximize synergies to bring new therapies to patients faster Generate added value for both partners Develop new therapies for Geographic Atrophy and wet AMD Provides access to capital and drug discovery and development expertise Financial commitment Strategic insight and access to scientific and technological expertise Access to Ophthalmology Development expertise with proven track record Page 20 Kemal Malik, high-tech partnering conference, February 2015
21 Bayer: Science For A Better Life a Mission born out of our Spirit Innovation Culture External Innovation Frameworks promoting Innovation Page 21 Kemal Malik, high-tech partnering conference, February 2015
22 Thank you!
Developing a path to Innovation through Collaboration
Developing a path to Innovation through Collaboration Adrian Percy, Head of Research and Development, Bayer Crop Science Division London October 18, 2017 Moving from closed Innovation towards Innovation
Outsourcing biopharmaceuticals manufacturing Best practices when working with external supply partners
Outsourcing biopharmaceuticals manufacturing Best practices when working with external supply partners Dr. Ulrich Rümenapp, Bayer AG Biologics & Biosimilars Congress 1-2 February 2016 Berlin, Germany Outline
From Science to Value. Introduction to VIB s tech transfer activities
From Science to Value Introduction to VIB s tech transfer activities VIB s mission Conduct frontline life sciences research Excellence in Science and Innovation Translate results into benefits for society
Takeda akeda Research esearch Investment, Inc. nc. 435 Tasso Street, Suite 300 Palo Alto, CA94301 USA. Tel: +1 (650)
Takeda akeda Research esearch Investment, Inc. nc. 435 Tasso Street, Suite 300 Palo Alto, CA94301 USA Tel: +1 (650) 328 2900 www.tri-takeda.com 2 3 4 5 www.tri-takeda.com Operations started April 2002
Partnering with Technology Companies to Advance Medical Device Innovation
Partnering with Technology Companies to Advance Medical Device Innovation Pierre R. Theodore, M.D. Vice President, Medical Devices Johnson and Johnson Innovation UCSF Health Sciences Clinical Associate
DuPont: Building Higher Growth, Higher Value Through Science Douglas Muzyka, Ph.D. Senior Vice President; Chief Science & Technology Officer
DuPont: Building Higher Growth, Higher Value Through Science Douglas Muzyka, Ph.D. Senior Vice President; Chief Science & Technology Officer Regulation G The attached charts include company information
IMPA 2 CT REPORT 017
IMPACT REPORT 2017 2017 78 Companies Served Since 2014 37 Alumni Companies by Year s End $2,015,429,000 in Funding Raised Since 2014 $760,215,000 in 2017 Funding Raised 63 Net Promoter Score BY THE NUMBERS
2017 SRA International Annual Meeting. Dr. Eli Even, Head of Research Authority Bar-Ilan University, Israel
2017 SRA International Annual Meeting Dr. Eli Even, Head of Research Authority Bar-Ilan University, Israel October 14-18, 2017 PERSONAL INTRODUCTION PhD in Applied Chemistry, The Hebrew University, Jerusalem
Credit Suisse Chemical & Ag Science Conference
Credit Suisse Chemical & Ag Science Conference Ellen Kullman Executive Vice President E. I. du Pont de Nemours and Company September 17, 2008 New York 2 Regulation G The attached charts include company
StarTAU Tel Aviv University Entrepreneurship Center 1
StarTAU Tel Aviv University Entrepreneurship Center 1 Tel Aviv University Tel Aviv University (TAU), Founded in 1956, is the largest and most comprehensive institution of higher learning and research in
AN OVERVIEW OF THE ISRAELI MEDICAL DEVICES INDUSTRY
The global healthcare systems are facing many challenges. Aging populations and burgeoning middle classes along with expectations of higher-quality care and a squeeze on funding have created a drive for
Is the EIT a model for realizing the knowledge triangle?
Is the EIT a model for realizing the knowledge triangle? Alexander von Gabain Chairman of the EIT Governing Board 30th Conference of Rectors & Presidents of European Universities of Technology, Sept 2011,
Flagship VentureLabs Fellows Program
Flagship VentureLabs Fellows Program Where Exceptional Innovator-Entrepreneurs Help Create the Next Disruptive Life Science Startups A Unique Life Science Innovation Enterprise Flagship Pioneering is a
Scaling innovation for impact
Re: ED12.2 Scaling innovation for impact Karen Greve Young, VP Partnerships kgreveyoung@marsdd.com MAY 2016 Visit us at marsdd.com Toronto Canada s Global Innovation City 6 million people in GTA 4 th largest
NFMRI. National Foundation for Medical Research and Innovation. Impact giving Advancing medical innovations
NFMRI National Foundation for Medical Research and Innovation Impact giving Advancing medical innovations Philanthropy has the freedom to think different, do different, & make a difference. Medical innovation
presents OHIO biomedical and pharma career fair April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet
presents OHIO biomedical and pharma career fair 2013 April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet Exhibitors Aerotek Scientific Alliance Scientific Amylin Ohio Aptalis Pharmatech Cardinal Health Diagnostic
Business Globalization
EMC 2 Global Innovation Conference Santa Clara, CA, October 31, 2012 Business Globalization and the Importance of Entrepreneurial Innovation Richard B. Dasher, Ph.D. Director, US-Asia Technology Management
Life Sciences Outlook
Greater Toronto 2018 JLL Research Report Life Sciences Outlook Breakthrough discoveries at a breathtaking pace 2 Greater Toronto The Greater Toronto area is home to Canada s largest combined life sciences
BEST PLACE FOR BUSINESS & CAREERS 1. 1st BEST PLACE TO DO BUSINESS 5
1 CONTENTS Doing Business in Colorado A Diverse Portfolio of Industries Business Funding and Incentives Capital Major Employers, Recent Relocations & Expansions Colorado s Talent & Knowledge Base Life
Dec LILLE, France. 7 th. edition. A 360 approach to source early-stage innovations in Life Sciences. Organised by: In collaboration with:
LILLE, France 4 th & 5 th Dec. 2018 7 th edition A 360 approach to source early-stage innovations in Life Sciences Organised by: In collaboration with: BioFIT at a glance BioFIT is the leading partnering
Business acceleration schemes for start-ups
Business acceleration schemes for start-ups Focus on internationalisation A Policy Brief from the Policy Learning Platform on SME Competitiveness Introduction Business acceleration programmes, which aim
European Investment Fund in Support of Tech Transfer
European Investment Fund European Investment Fund in Support of Tech Transfer This presentation was prepared by EIF. Any estimates and projections contained herein involve significant elements of subjective
MRC Funding and Translational Research. Dr Catriona Crombie
MRC Funding and Translational Research Dr Catriona Crombie Medical Research Council The Medical Research Council is dedicated to improving human health through the best scientific research. Its work, on
National Grid Ventures. Lisa Lambert, SVP, CTIO June 2018
National Grid Ventures Lisa Lambert, SVP, CTIO June 2018 Lisa Lambert Education MBA, Harvard Business School BS/MIS, Pennsylvania State University Executive Education, Stanford University UPWARD www.upwardwomen.org/
Chapter 02 Sources of Innovation
Chapter 02 Sources of Innovation True/False 1. Sometimes knowing a field too well can stifle creativity. Page: 19 2. The organization s structure, routines, and incentives can thwart individual creativity,
Massachusetts Programs & Initiatives Advancing the Biopharmaceutical Industry
Massachusetts Programs & Initiatives Advancing the Biopharmaceutical Industry Massachusetts State Profile 5 Key Programs & Initiatives The opportunities generated by the biopharmaceutical sector as a leader
Technion Technology Transfer Connecting Partners to Find Solutions
Technion Technology Transfer Connecting Partners to Find Solutions 2016 http://blog.compass.co/the-2015-global-startup-ecosystem-ranking-is-live The Global Startup Ecosystem Ranking 2015 Israeli Venture
ACCELERACE LIFE SCIENCE, BIOTECH & MEDTECH
ACCELERACE LIFE SCIENCE, BIOTECH & MEDTECH EUROPE S LEADING ACCELERATOR WHAT WE DO SPOT WE ATTRACT AND SELECT THE BEST STARTUPS AND TALENTS IN THE WORLD TRAIN WE DEVELOP STARTUPS IN ORDER TO UNLEASH THEIR
UBM CAPITAL MARKETS DAY
UBM CAPITAL MARKETS DAY Capital Markets Day Introduction Disclaimer This presentation contains statements which are not based on current or historical fact and which are forward looking in nature. These
RFA/PA: HL PCC: HH N
PROGRAM CONTACT: KATHLEEN ROUSCHE 301-594-5507 kathleen.rousche@nih.gov Principal Investigator ICHAEL J PHD SUMMARY STATEMENT ( Privileged Communication ) Release Date: 05/17/2013 Revised Date: 05/21/2013
Investor Presentation
Investor Presentation Q4 FY 2017 Content India Improved rankings Exports Rupee appreciation hurting Financial Highlights Consistent Performance Infrastructure Plan, Prepare, Perform 2 of 33 India 3 of
fosters, protects, accelerates, and funds early stage innovation
Innovate@UIC fosters, protects, accelerates, and funds early stage innovation A vision to better align the commercialization efforts at UIC EWC OTM The linear model had discrete connections between the
Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business Research Store is run by Sector Publishing Intelligence
Investor Presentation Q1 FY 2017
Investor Presentation Q1 FY 2017 www.ajantapharma.com 1 of 27 Content Financial Highlights Industry Update India Financial Highlights Emerging Markets USA Infrastructure 2 of 27 India 3 of 27 India Branded
Improving patient outcomes & health economics through connected health innovation
Improving patient outcomes & health economics through connected health innovation Session 103, February 21, 2017 Jeroen Tas, Chief Innovation & Strategy Officer, Philips Dr. Kevin Dellsperger, MD, PhD,
New York Life Sciences Initiative
New York Life Sciences Initiative Initiative Real Estate - Underway JLABS Jan-17 30,000 SF incubator that will provide pre-built office and wet lab space for ~30 early stage life sciences companies, as
Mediwales Finance and Funding Event:
Mediwales Finance and Funding Event: Cardiff, March 22 nd 2012 Translational Research Funding for Companies Dr Tim Knott Business Development Manager, Technology Transfer The Wellcome Trust Overview of
Canadian Accelerators
Canadian Accelerators Company Focus Conditions Description Sherbrooke,QC Innovative firms and/or start-up technologies Cash investment up to $20,000, professional services in kind, and 5% equity investment
Rajendra Mishra School of Engineering Entrepreneurship Indian Institute of Technology, Kharagpur , INDIA
Detailed Dual Degree Course Structure at RMSOEE 1. Basic entrepreneurship (EP 60001) Entrepreneurial traits, true motivation & leadership, understanding of Entrepreneurial process,
ED28.1. MaRS Discovery. District. Yung Wu CEO. Cory Mulvihill Lead Executive, Policy & Public Affairs. MaRS OVERVIEW / 1
MaRS Discovery ED28.1 2018 District Yung Wu CEO Cory Mulvihill Lead Executive, Policy & Public Affairs MaRS OVERVIEW / 1 TORONTO AS A HUB FOR CANADA S CONVERGENT INNOVATION Strongest Patenting and VC Investment
Luc Gregoire Chief Financial Officer. Internet & Technology Services Conference. February,
Luc Gregoire Chief Financial Officer Cantor Fitzgerald 4 th Annual Internet & Technology Services Conference February, 23 2017 Cantor Fitzgerald 4 th Annual Internet & Technology Services Conference February
Johns Hopkins Technology Ventures:
Johns Hopkins Technology Ventures: Converting our groundbreaking research to products October 2016 1 Johns Hopkins University + Hospital $1.95B+ national leader in NIH research funding 36 Nobel laureates
Access to finance for innovative SMEs
A policy brief from the Policy Learning Platform on SME competitiveness July 2017 Access to finance for innovative SMEs Policy Learning Platform on SME competitiveness Introduction Entrepreneurship is
The Role of the Research Enterprise in Economic Development
The Role of the Research Enterprise in Economic Development Board of Trustees Workgroup Research and Health Sciences April 17, 2008 Karen A. Holbrook Vice President for Research and Innovation Science
DSM Transformation: The Learning Cycle of Innovation Hein Schreuder Vlerick Business School
DSM Transformation: The Learning Cycle of Innovation Hein Schreuder Vlerick Business School Untill 2012: Executive Vice President Corporate Strategy & Acquisitions Royal DSM N.V. Our history Coal Mining
VTT Venture Oy. VTT:n media-aamiainen Antti Sinisalo, CEO VTT Ventures Oy
12.10.2011 1 VTT Venture Oy VTT:n media-aamiainen 13.10.2011 Antti Sinisalo, CEO VTT Ventures Oy 12.10.2011 2 Role Develops spin-off companies based on VTT s technology Makes pre-seed and seed phase investments
Early Access Programs (EAPs)
Initiating in Europe: Five Things to Consider Executive Insight s Morteza Yazdani and Francesca Boggio look at the the specific considerations for launching an Early (or Expanded) Access Program in Europe.
Pharma Investment in Digital Health: Strategies for success
A FirstWord ExpertViews Dossier Report Request Access To This Report HERE Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or
IKP Knowledge Park. Deepanwita Chattopadhyay Chairman & CEO
IKP Knowledge Park Deepanwita Chattopadhyay Chairman & CEO Genesis Hypothesis: Innovation, especially scientific and technological innovation, a key differentiator for economic prosperity The Central Theme
Connecting Startups to VC Funding in Canada
Technology & Life sciences Connecting Startups to VC Funding in Canada introduction While the majority of respondents have accessed early seed investment from friends, family and angel investors, many
Strategies for attracting healthcare venture capital
Beth Silverstein MS, RAC is the Director of SciLucent, LLC, a USbased management, regulatory and technical services consulting firm dedicated to helping healthcare product companies maximise the value
Venture Capital since 1997
Venture Capital since 1997 We empower tech-companies with capital and engagement bmp Ventures AG 2017 www.bmp.com S. 1 bmp Ventures at a glance 50+ portfolio companies Early/Growth investment phase 90m+
Startup Success Stories
Last updated: May 2017 Europe's leading company for online event management and ticketing. Founded in 2006, financing rounds with VC investors and business angels. Winner of the 2009 Techcrunch Europe
San Francisco January 22-24, 2018
San Francisco January 22-24, 2018 Nurturing the Next Generation of Entrepreneurs: Thank What you does success look like, and for whom? #cleantechsf Nurturing the Next Generation of Entrepreneurs: What
Submission to the R&D tax environment review
Submission to the R&D tax environment review BioIndustry Association February 2017 Summary The UK s world-leading life sciences sector contributes more than 60bn a year to GDP 1, and generates exports
Investor Presentation 3 rd Qtr. - FY 2018
Investor Presentation 3 rd Qtr. - FY 2018 25 th January, 2018 1 of 34 Content Content INDIA 1 India 2 Global 3 Infrastructure 4 Financial Highlights 5 Recognition 2 of 34 INDIA 1 India 3 of 34 India Branded
Digital Health Funding Rankings
Published: April 1, 2015 StartUp Health Insights TM Digital Health Funding Rankings Q3 2015 Report INCLUDING 50+ MARKET FUNDING SPONSORED BY A StartUp Health Insights TM Report Published October 1, 2015
THIS IS THE LARGEST GATHERING OF ALL LIFE SCIENCES SPECIALISTS IN THE ENTIRE CENTRAL AND EASTERN EUROPE.
DEAR GUESTS, It is my honor and privilege to invite you to the third international Forum "Life Sciences Baltics 2016", which will be held in Vilnius, Lithuania, on September 14-15, 2016. This bi-annual
Innovation Academy. Business skills courses for Imperial Entrepreneurs
INNOVATION ACADEMY Innovation Academy Business skills courses for Imperial Entrepreneurs Innovation Academy Business skills courses for Imperial entrepreneurs Imperial Innovations has launched Innovation
ISRAEL- UKRAINIAN INNOVATION EXPO 2018 ROADSHOW. Roadshow Discovery by
ISRAEL- UKRAINIAN INNOVATION EXPO 2018 ROADSHOW Roadshow Discovery by WHO WE ARE We connect startups, large corporations, Investors and technology consultants with the exciting Israeli startup ecosystem.
Supporting Startups and Growing Our Own. The Future of Jobs Summit 2013 Innosphere Overview
Supporting Startups and Growing Our Own The Future of Jobs Summit 2013 Innosphere Overview Accelerating entrepreneurship and job creation for 14 years 501(c)3 non-profit organization + Colorado Enterprise
Program Objectives. Your Innovation Primer. Recognizing and Organizing for Innovation THE INNOVATIVE ORGANIZATION
1 2 3 4 5 Your Innovation Primer Recognizing and Organizing for Innovation Profiting from Technology Driven Innovation The Innovation Process Tools for Strategy and Implementation Innovation in Action
R E Q U E S T F O R A P P L I C A T I O N S
R E Q U E S T F O R A P P L I C A T I O N S RFA C-12-INCU-2 Texas Life Science Incubator Infrastructure Awards 2011 2012 Fiscal Year Award Period September 1, 2011 August 31, 2012 CPRIT RFA C-12-INCU-2
ESTONIA STARTUP ECOSYSTEM REPORT
ESTONIA STARTUP ECOSYSTEM REPORT from by The Startup Ecosystem Report Series Compass.co (formerly Startup Genome) with the support of CrunchBase Jan 2016, Version 1.0 2 ABOUT COMPASS.CO (FORMERLY STARTUP
DIGITAL MADE IN ITALY
DIGITAL MADE IN ITALY The leading innovation hub European Mid Small Cap Forum Alberto Fioravanti, Digital Magics Founder and Executive Chairman Alessandro Malacart, Digital Magics Managing Director Corporate
Houston s early-stage life science commercialization platform. Evolving a Novel Approach to Life Sciences Commercialization
Houston s early-stage life science commercialization platform Evolving a Novel Approach to Life Sciences Commercialization CPRIT Conference, November 2017 Texas Medical Center City of Medicine TMC Key
GLOBAL CITIZENSHIP HIGHLIGHTS
GLOBAL CITIZENSHIP HIGHLIGHTS ABBOTT TODAY BALANCED We are a well-balanced company, with four major businesses of roughly equal size. We re able to capture opportunities across the spectrum of healthcare,
On Site Health Clinics: Effectively Managing Initial Costs and Incorporating Innovative/Effective Programs
On Site Health Clinics: Effectively Managing Initial Costs and Incorporating Innovative/Effective Programs Health Plan Overview: Where We Were In 2009/2010 Fully Insured through BCBS of Florida Covered
Models for Innovation
Models for Innovation Moderator: Larry Stofko, EVP The Innovation Institute DISCLAIMER: The views and opinions expressed in this presentation are those of the author and do not necessarily represent official
VISION. Orange County will become a national and global leader in scalable innovation.
A P P L I E D I N N O V A T I O N VISION Orange County will become a national and global leader in scalable innovation. MISSION Startups UCI will be the UCI catalyst for innovation & entrepreneurship in
CLUSTER POLICIES AND KNOWLEDGE EXCHANGE
CLUSTER POLICIES AND KNOWLEDGE EXCHANGE A case study of the Port of Rotterdam Workshop on Maritime Clusters and Economic Challenges, 1 December 2016 Andrea-Rosalinde Hofer Centre for SMEs, Local Development
THE DIGITAL REVOLUTION IN ITALY
THE DIGITAL REVOLUTION IN ITALY 1 of 14 PROSPECTS FOR THE DIGITAL MARKET IN ITALY ACCENTURE S REPORT 'DIGITAL DISRUPTION: THE GROWTH MULTIPLIER' WORLD ECONOMIC FORUM IN DAVOS, JANUARY 2016 For Italy, a
Call for organisations to cooperate with EIT Health as EIT Health Hubs within the EIT Regional Innovation Scheme 2018
EIT Health Call for organisations to cooperate with EIT Health as EIT Health Hubs within the EIT Regional Innovation Scheme 2018 Submission Deadline: March 2, 2018, 17:00 (CET) Contact: Judit Hegedüs (judit.hegedus@eithealh.eu)
Analysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas
Analysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas September 13, 2012 BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON
RWJMS Strategic Plan
RWJMS Strategic Plan 2016-2021 Rutgers, The State University of New Jersey Table of Contents Overview 3 Organizational Direction (Mission, Vision, Values) 6 Strategic Priorities Education 11 Research 17
The. fast track. innovation: for. UK has a hands-on role B y K acie P. M iller and Linda Perr y
The fast track for innovation: UK has a hands-on role B y K acie P. M iller and Linda Perr y President Matt Bellis (left) and Daniel Lau, chief technology officer and UK associate professor of electrical
Enabling Biotechnology Innovation Regime in the Country
Enabling Biotechnology Innovation Regime in the Country Dr Jitendra Kumar Vice President, Life Science Incubator, IKP Knowledge Park, Hyderabad July 10, 2012 Role of Various Agencies in Boosting Innovation
Life sciences and health technologies. A wealth-generating sector and a creator of prosperity for Quebec
Life sciences and health technologies A wealth-generating sector and a creator of prosperity for Quebec Highlights of the life sciences and health technologies sector (LSHT) A critical sector for Greater
1.5. Indo-German-Swiss Bootcamp Calling Entrepreneurs for
Calling Entrepreneurs for nd th April 2 April 11, 2018 Exchange between Indian, German and Swiss Start-Ups in the Healthcare Sector 1.5 week Bootcamp Start-ups in India 15from India, Germany & Switzerland
Boston MedTech Advisors
Boston MedTech Advisors BOSTON GERMANY ISRAEL www.bmtadvisors.com www.bmtcrogroup.com 990 Washington Street, Dedham, MA 02026 Ph. 781.407.0900 More Experience Better Results 1 Market Dev. Business Dev.
From Crisis to Start-Up City
From Crisis to Start-Up City THE NEW YORK CITY STORY Mark A. Thomas New York City Economic Development Corporation Senior Vice President - Partnerships MY ROLE @ NYCEDC Strategic private sector engagement
Programs & Initiatives Advancing the Biopharmaceutical Industry
Tennessee Programs & Initiatives Advancing the Biopharmaceutical Industry Tennessee State Profile 1 Key Programs & Initiatives The opportunities generated by the biopharmaceutical sector as a leader in
Go-To-Market Program. Go Global From The Start. Born2Global Road Map. Global Membership Services. Why Choose Born2Global?
Born2Global Road Map Startup Campus K-Global Startup Hub Global Membership Services Go-To-Market In-house Experts Go-To-Market Channel Partners Go-To-Market Program Practice Entrepreneurs Week Seminar
IN OUR ENTREPRENEUR ECOSYSTEM, THE SUCCESS STORIES DON T STOP
IT S ON IN OHIO IN OUR ENTREPRENEUR ECOSYSTEM, THE SUCCESS STORIES DON T STOP OUR DIGITAL STARTUPS ARE PARTNERING UP. By embracing the entrepreneurial spirit, Ohio has created a culture that cultivates
Korean Academy of Science and Technology
Korean Academy of Science and Technology November 20, 2003 Presentation by Thomas F. George, Ph.D. Chancellor and Professor of Chemistry & Physics University of Missouri-St. Louis I. Evolution of Academic
Synergies between the EIT, its. Innovation Communities and the NCPs A sustainable energy future for Europe, by EIT InnoEnergy
Synergies between the EIT, its Innovation Communities and the NCPs A sustainable energy future for Europe, by EIT InnoEnergy Agenda www.innoenergy.com 1 Our mission Our structure and locations Our activities
JOHNS HOPKINS TECHNOLOGY VENTURES. Help Us Bring Life-Changing Innovations from Hopkins and Baltimore to the World
Help Us Bring Life-Changing Innovations from Hopkins and Baltimore to the World POWERING THE FUTURE OF ENTREPRENEURSHIP AT HOPKINS In 1912, John Abel, a Johns Hopkins scientist, pioneered an early form
CAMBRIDGE OFFICE & LAB MARKET REPORT
CAMBRIDGE OFFICE & LAB MARKET REPORT FIRST QUARTER 2018 MUST HAVE LOCATION & INNOVATION HUB As Greater Boston s gateway market, Cambridge is a magnet for intellectual capital, innovative minds and technological
NON- GOVERNMENTAL ORGANIZATION (NGO) OVERVIEW
NON- GOVERNMENTAL ORGANIZATION (NGO) OVERVIEW *Merck & Co., Inc., based in Kenilworth, N.J., U.S.A. is known as MSD outside the United States and Canada. ABOUT THE MSD FELLOWSHIP FOR GLOBAL HEALTH
European Investment Fund: Venture Capital Financing in Bulgaria
European Investment Fund: Venture Capital Financing in Bulgaria 21 st June 2017 Hristo Stoyanov, Regional Business Development - CEE EIF with crucial role in supporting SMEs across Europe Resources Institutions
enture Accelerators in U.S
enture Accelerators in U.S STEPI International Symposium Global Entrepreneurship & Startup Ecosystems STEPI Korea Entrepreneurship Foundation 2015.5.28 Mukesh Patel, J.D. Copyright 2015 Mukesh Patel. All
session on Preparation
Mentoring Clinics 2016/20 Talk and One on One mentoring session on Preparation for 9th Call of Biotechnology Ignition Grant (BIG) for Entrepreneurs and Innovators Organized by Venturee Center, Pune POTENTIAL
JOB VACANCY AT EIT FOOD / CLC North-West
JOB VACANCY AT EIT FOOD / CLC North-West JOB TITLE: Programme manager BUSINESS CREATION European Institute of Innovation and Technology (EIT) Food is a young and fast growing organisation focusing on entrepreneurship
2018 Support Prospectus
Making LIFE Better It s what Arizona s Bioscience Industry is about and why the road from discovery to development to delivery is so important for people in Arizona and around the world. 2018 Support Prospectus
Confronting the Challenges of Rare Disease:
Confronting the Challenges of Rare Disease: SOLUTIONS ACROSS THE ENTIRE PRODUCT LIFE CYCLE The Orphan Drug Act of 1983 brought increased awareness to the need for new treatments for rare disease patients
Entrepreneurship and Innovation Ecosystems in a Corporate Environment: 3D Printing a House
Entrepreneurship and Innovation Ecosystems in a Corporate Environment: 3D Printing a House Dr. Paolo Bavaj Lux Research Summit Amsterdam, Personal Profile Paolo Bavaj Educational background: PhD in Chemistry,
Changing the World in a Company
Changing the World in a Company 29 Jan 2014 Classification: INTERNAL USE ONLY 2 Classification: INTERNAL USE ONLY Shifting mindsets 3 Classification: INTERNAL USE ONLY 4 Classification: INTERNAL USE ONLY
Beating the benchmark
Beating the benchmark Peter Brabeck Chairman & Chief Executive Officer 11 January 2007 Bellevue meets management seminar January 2007 Disclaimer This presentation contains forward looking statements which
The Ultimate Guide to Startup Success:
The Ultimate Guide to Startup Success: Launching a startup is an exciting prospect, but one that is also fraught with considerable challenges. Bringing a new idea to the marketplace requires more than
Drug Innovations Coming From Outside Big Pharma
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/drug-innovations-coming-from-outside-bigpharma/3524/